Phase II Trial of Concurrent Paclitaxel, Carboplatin and External Beam Radiotherapy Followed by Surgical Resection in Stage IIIA (N2) Non-Small Cell Lung Cancer
- Determine the response rate, duration of response, and survival in patients with bulky
stage IIB or stage IIIA non-small cell lung cancer treated with paclitaxel,
carboplatin, and radiotherapy followed by surgical resection.
- Assess the toxicity of this regimen in this patient population.
OUTLINE: This is a multicenter study.
Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes weekly for 5
weeks. Patients also undergo concurrent radiotherapy daily 5 days a week for 5 weeks in the
absence of unacceptable toxicity. At approximately 4 weeks after completion of
chemoradiotherapy, patients with stable or regressive disease undergo surgical resection. If
disease is unresectable, patients receive an additional 2 weeks of radiotherapy.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
PROJECTED ACCRUAL: A total of 29-30 patients will be accrued for this study.
Primary Purpose: Treatment
Pathologic response rate as measured by pathology of the resected specimen and chest x-ray at 3 and 5 years after completion of study treatment
David J. Perry, MD
Washington Hospital Center
United States: Federal Government
|Washington Cancer Institute at Washington Hospital Center||Washington, District of Columbia 20010|
|Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center||Baltimore, Maryland 21237|